{"id":10475,"date":"2010-06-01T15:22:52","date_gmt":"2010-06-01T15:22:52","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=10475"},"modified":"2010-06-01T15:22:52","modified_gmt":"2010-06-01T15:22:52","slug":"development-of-apricitabine-halted-without-finding-backer-for-phase-3","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/10475","title":{"rendered":"Development of apricitabine halted without finding backer for Phase 3"},"content":{"rendered":"<p>On 10 May 2010, the Australian biotechnology company Avexa, announced the closure of the development programme for the nucleoside apricitabine (AVX754).<\/p>\n<p>According to an earlier statement in March, initial three-week results from the study suggest activity against HIV with M184V mutation, associated with high-level resistance to 3TC and FTC.<\/p>\n<p>Apricitabine is a cytidine analogue similar to 3TC and 48-week results from Phase 2b studies were presented at the HIV Congress in Glasgoew in 2008. [2]<\/p>\n<p>Avexa were developing apricitabine under license from Shire Pharmaceuticals.<\/p>\n<p>References<\/p>\n<p>1.\t\tAvexa Press Statement (10 May 2010).<\/p>\n<p><a href=\"http:\/\/www.avexa.com.au\/freestyler\/files\/Avexa%20closes%20apricitabine%20program.pdf\">http:\/\/www.avexa.com.au\/freestyler\/files\/Avexa%20closes%20apricitabine%20program.pdf<\/a><\/p>\n<p>2.\t\tCahn P et al. 48-week data from Study AVX-201 \u0096 A randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. 9th International Congress on Drug Therapy in HIV Infection Glasgow, 9\u009613 November 2008.\u00a0Abstract O414.<\/p>\n<p><a href=\"http:\/\/www.springerlink.com\/content\/j316274167445388\/fulltext.pdf\">http:\/\/www.springerlink.com\/content\/j316274167445388\/fulltext.pdf<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 10 May 2010, the Australian biotechnology company Avexa, announced the closure of the development programme for the nucleoside apricitabine (AVX754). According to an earlier statement in March, initial three-week results from the study suggest activity against HIV with M184V &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-10475","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=10475"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/10475\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=10475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=10475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=10475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}